-
Implementation outcomes included in NIDA Clinical Trials Network (CTN) studies: A systematic review of studies conducted over 20 years.
Gonzalez ST, Horigian VE, Cheng H, Hagedorn HJ, Shmueli-Blumberg D, Campbell CI, Lin C, Rogers E, Baloh J, Hilton R, Vena A, McNeely J, Glass JE. Implementation outcomes included in NIDA Clinical Trials Network (CTN) studies: A systematic review of studies conducted over 20 years. Journal of Substance Use and Addiction Treatment 2025 (in press).
-
Risks for adverse events by sex and age after prescription opioid dose reduction: Secondary analysis across 8 U.S. health systems.
Metz VE, Palzes V, Binswanger IA, Altschuler A, Poulsen MN, Ahmedani BK, Andrade SE, Clark RE, Hechter RC, Horberg M, Sanchez K, Bailey SR, Stephens KA, Rubinstein AL, Campbell CI. Risks for adverse events by sex and age after prescription opioid dose reduction: Secondary analysis across 8 U.S. health systems. American Journal of Preventive Medicine 2025;69(6):108085.
-
Delivering opioid use disorder treatment among American Indian and Alaska Native adults during the COVID-19 pandemic and beyond: Facilitators and barriers to care.
Hirchak KA, Bajet K, Richardson M, Keyes B, Shaffer R, Oliver KA, Kropp FK, Campbell ANC, Vennder KL. Delivering opioid use disorder treatment among American Indian and Alaska Native adults during the COVID-19 pandemic and beyond: Facilitators and barriers to care. Journal of Ethnicity in Substance Abuse 2025 (in press).
-
Clinical decision support system for primary care of opioid use disorder: A randomized clinical trial.
Rossom RC, Crain AL, Wright EA, Haller I, Haapala J, Dehmer SP, Solberg L, O'Connor PJ, Borgert-Spaniol C, Gorodisher J, Miley K, Romagnoli K, Allen C, Tusing L, Ekstrom H, Appana D, Sperl-Hillen JM, Kobylinski M, Huntley K, McCormack J, Chen W, Bart G. Clinical decision support system for primary care of opioid use disorder: A randomized clinical trial. JAMA Internal Medicine 2025;185(9):1079-1089.
-
Suicidal ideation in adults with opioid use disorder treated with buprenorphine-naloxone versus extended-release naltrexone.
Rizk MM, Stanley B, Choo T, Pavlicova M, Scodes JM, Rotrosen J, Nunes EV. Suicidal ideation in adults with opioid use disorder treated with buprenorphine-naloxone versus extended-release naltrexone. American Journal of Drug and Alcohol Abuse 2025;51(4):658-666.
-
Understanding the characteristics and comorbidities of primary care patients with risky opioid use: Baseline data from the multi-site “Subthreshold Opioid Use Disorder Prevention” (STOP) trial.
Rostam-Abadi Y, Liebschutz JM, Subramaniam G, Stone R, Appleton N, Mazel S, Alexander K, Brill SB, Case A, Gelberg L, Gordon AJ, Hong H, Incze MA, Kawasaki SS, Kim T, Kline M, Lovejoy TI, McCormack J, Zhang S, McNeely J. Understanding the characteristics and comorbidities of primary care patients with risky opioid use: Baseline data from the multi-site "Subthreshold Opioid Use Disorder Prevention" (STOP) trial. Journal of General Internal Medicine 2025;40:2906-2915.
-
Exploring clinical profile and treatment outcome differences based on baseline smoking and alcohol co-use status among individuals initiating medication for opioid use disorder treatment.
León G, Bae J, Coles C, Batts C, Schmidt A, Akana N, Smith CL, McPherson SM, Miguel A. Exploring clinical profile and treatment outcome differences based on baseline smoking and alcohol co-use status among individuals initiating medication for opioid use disorder treatment. American Journal on Addictions 2025;35(1):85-89.
-
“PrEP is always on the table”: Mixed methods study of provider willingness to refer/link clients to PrEP in community sexual health and drug use-related programs.
Paschen-Wolff MM, Laschober TC, Spector AY, Ertl MM, Nelson CM, Hatch MA, Lancaster C, Wright L, Tross S. "PrEP is always on the table": Mixed methods study of provider willingness to refer/link clients to PrEP in community sexual health and drug use-related programs. Journal of HIV/AIDS & Social Services 2025 (in press).
-
Why is substance use missing from my patient’s problem list? CTN research to advance screening, prevention, and treatment of substance use in primary care [commentary].
McNeely J, Bradley KA, Liebschutz JM, Subramaniam GA. Why is substance use missing from my patient's problem list? CTN research to advance screening, prevention, and treatment of substance use in primary care [commentary]. Journal of Substance Use & Addiction Treatment 2025;209780 (in press).
-
Craving, impulsivity, and subsequent methamphetamine use with naltrexone-bupropion versus placebo: Findings from a randomized clinical trial.
Jha MK, Ghitza UE, Carmody T, Kuruvila N, Shoptaw S, Minhajuddin A, Wakhlu S, Schmitz JM, Coffin PO, Bart G, Nunes EV, Kenny P, Trivedi MH. Craving, impulsivity, and subsequent methamphetamine use with naltrexone-bupropion versus placebo: Findings from a randomized clinical trial. Journal of Addiction Medicine 2025 (in press).